NDRG2 Ameliorates Hepatic Fibrosis by Inhibiting the TGF-β1/Smad Pathway and Altering the MMP2/TIMP2 Ratio in Rats

Jiandong Yang1,2,*, Jin Zheng3,*, Lin Wu2,*, Ming Shi4,*, Hongtao Zhang1, Xing Wang1, Ning Xia1, Desheng Wang1, Xinping Liu2, Libo Yao2, Yan Li2,*, Kefeng Dou1*

1 Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China, 2 Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi’an, China, 3 Department of Traditional Chinese and Western Medicine of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China, 4 Department of Neurology, Xijing Hospital, The Fourth Military Medical University, Xi’an, China

Abstract

Liver fibrosis is a worldwide clinical issue. It has been well established that activated hepatic stellate cells (HSCs) are responsible for excessive extracellular matrix (ECM) deposition in chronically damaged livers. The identification of key elements that control HSCs activation will help to further our understanding of liver fibrosis and improve the outcome of clinical treatment. This study demonstrates that N-Myc downstream-regulated gene 2 (NDRG2) is a potential regulator of liver fibrosis as NDRG2 mRNA and protein levels were reduced during HSCs activation. In addition, enhanced NDRG2 expression reduced Smad3 transcription and phosphorylation, which inhibited HSCs activation by blocking the TGF-β1 signal. Moreover, NDRG2 contributed to an increase in the ratio of matrix metalloproteinase 2 (MMP2) to tissue inhibitor of matrix metalloproteinase 2 (TIMP2), which may facilitate the degradation of the ECM. In dimethylnitrosamine (DMN)-induced fibrotic rat livers, adenovirus-mediated NDRG2 overexpression resulted in decreased ECM deposition and improved liver function compared with controls. In conclusion, the present findings indicate that the modulation of NDRG2 is a promising strategy for the treatment of liver fibrosis.

Citation: Yang J, Zheng J, Wu L, Shi M, Zhang H, et al. (2011) NDRG2 Ameliorates Hepatic Fibrosis by Inhibiting the TGF-β1/Smad Pathway and Altering the MMP2/TIMP2 Ratio in Rats. PLoS ONE 6(11): e27710. doi:10.1371/journal.pone.0027710

Editor: Ching-Ping Tseng, Chang Gung University, Taiwan

Received July 26, 2011; Accepted October 22, 2011; Published November 16, 2011

Copyright: © 2011 Yang, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Natural Science Foundation of China Grants 81072973; 81100764; 30830054; 31070681; 81170400. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lsq@mumu.edu.cn (YL); doukef@163.com (KD)

These authors contributed equally to this work.

Introduction

Liver fibrosis is a major medical problem of liver diseases, especially in Asian countries. Chronic hepatitis, metabolic disorders, genetic mutations and cholestatic diseases are common causes of liver fibrosis and even cirrhosis and hepatocellular carcinoma (HCC) [1,2]. Substantial improvements in the treatment of liver fibrosis have been achieved due to continued studies [3,4,5], thereby prompting us to explore the mechanisms involved in the development of liver fibrosis and potential therapies that could inhibit the progression of fibrosis.

HSCs play a central role in liver fibrosis. In normal liver, HSCs are in a quiescent state and their main function is to store retinoids. However, during the development of hepatic fibrosis, chronic liver damage leads to HSCs activation, characterized by a transformation from the quiescent state to a proliferative, contractile and fibrogenic myofibroblast-like phenotype that terminates in excessive hepatic matrix deposition, liver function impairment, cirrhosis and organ failure [6,7].

The activation of HSCs is finely regulated by multiple pathways and factors, and of these, TGF-β1/Smad signaling is one of the major pathways in charge of HSCs activation, type I collagen expression and deposition. TGF-β1 binds to its receptor, leading to the phosphorylation of the intracellular mediators Smad2 and Smad3, which then form hetero-oligomers with a common mediator, Smad4. The complex then translocates from the cytoplasm to the nucleus to regulate gene transcription. The expression of inhibitory Smad7, which interacts with a group of ubiquitin ligases termed Smurf and degrades the TGF-β receptors through proteasomal and lysosomal pathways, is also induced by TGF-β signaling as part of a negative feedback loop [8,9]. In addition, TGF-β1 regulates the expression of matrix metalloproteinases (MMPs) and tissue inhibitor of matrix metalloproteinases (TIMPs). MMPs are endogenous peptidases capable of degrading various components of the basement membrane while TIMPs inhibit collagen degradation. In the fibrotic liver, the expression of MMPs and TIMPs are both increased [10] and it is the balance of MMPs and their tissue inhibitors that determines the progression and regression of ECM accumulation and liver fibrosis [11,12].

Recently, several studies have revealed that NDRG2 is a potent factor in regulating liver embryonic development, tissue remodeling and carcinogenesis. NDRG2 (GenBank Accession No. AF159092) belongs to the NDRG family, which comprises four members, NDRG1-4. Our laboratory initially identified human NDRG2, a cytoplasmic protein that is down-regulated by MYC and is involved in cell growth and differentiation, stress and
hormonal responses [13,14,15]. Accumulated data suggest that NDRG2 is closely involved in liver histogenesis and organogenesis as NDRG2 mRNA and protein levels are generally lower in the early stages and markedly higher during the later stages of histogenesis in mouse and human fetal livers of different gestational ages [16,17]. Our previous study demonstrated that NDRG2 could regulate liver regeneration by serving as a cell cycle and apoptosis regulator. As a new tumor suppressor gene [18,19,20], NDRG2 also plays a critical role in HCC, in which it is significantly down-regulated compared to adjacent normal tissues. Furthermore, high NDRG2 expression levels correlate positively with tumor differentiation and negatively with clinical parameters relevant to tumor metastasis. In vitro, it has been shown that NDRG2 affects the proliferative abilities of HCC cell lines [21] and antagonizes TGF-β-mediated HCC cell invasion by down-regulating MMP2 [22]. Additionally, when the dose expression profile for the whole liver during development of DMN-induced hepatic fibrosis, Takahara et al [23] found that NDRG2 was down-regulated in hepatocytes following fibrogenesis. Taken together, these data implicate the multiple functions of NDRG2 in liver under both normal and pathological conditions. However, to date, the significance of NDRG2 in the development of liver fibrosis has been little studied.

In the current study, we demonstrated that NDRG2 expression exhibited an inverse relationship with HSCs activation. In addition, we have shown that NDRG2 inhibited basal and TGF-β1-mediated HSCs activation via a reduction in Smad3 phosphorylation. Furthermore, adenovirus-mediated NDRG2 overexpression attenuated rat liver fibrosis and improved liver function by enhancing ECM degradation via the alteration of MMP2 and TIMP2 expression. In conclusion, our study is the first to explore the anti-fibrotic effects of NDRG2 in liver.

**Results**

**NDRG2 shows an inverse relationship with HSCs activation**

The spontaneously immortalized human HSCs cell line, LX-2, exhibits features typical of stellate cells, while the immortalized rat HSCs cell line, HSC-T6, exhibits features typical of myofibroblasts [24]. In this study, NDRG2 was expressed in LX-2 cells and was mainly localized to the cytoplasm, together with alpha smooth muscle actin (α-SMA), a marker of HSCs activation (Figure 1A). Previous studies have demonstrated that HSCs undergo further activation during growth and expansion on a plastic surface [25], and using this model we were able to assess the relationship between NDRG2 expression and LX-2 cell activation. After LX-2 cells grew to confluence, they were trypsinized and replated in 100 mm dishes for further activation. Over the next 12 days, increased expression of α-SMA was detected, indicating LX-2 activation while, in contrast, NDRG2 mRNA and protein expression decreased (Figure 1B and C). Similar results were observed in HSC-T6 cells (Figure S1).

TGF-β1 is a classic stimulator for HSCs activation and collagen production [26,27]. To confirm the relationship between NDRG2 and HSCs activation further, LX-2 cells were treated with TGF-β1 for 24 h after serum starvation. As expected, TGF-β1 increased LX-2 activation, as indicated by enhanced α-SMA levels compared to controls, while NDRG2 expression was inhibited (Figure 1D and E).

**NDRG2 inhibits HSCs activation**

Since NDRG2 was down-regulated during HSCs activation, adenovirus vectors were used to elevate NDRG2 expression transiently in LX-2 cells to determine the effect of NDRG2 on HSCs activation. The results showed that adenoviral vectors expressing NDRG2 (AdNDRG2) enhanced the level of NDRG2 compared to the negative control β-galactosidase (AdLacZ) group (Figure 2A and B). Next, the activation level of LX-2 cells was examined by staining the cells with adenovirus and/or TGF-β1. After treatment, both the basal and TGF-β1-induced α-SMA protein levels were decreased by NDRG2 overexpression (Figure 2C and D). These results indicated that NDRG2 could inhibit HSCs activation, even when mediated by TGF-β1.

**NDRG2 inhibits the TGF-β1/Smad signaling pathway and alters the relative levels of MMP2 to TIMP2**

TGF-β1 signaling is essential for HSCs activation and liver fibrosis. To gain a better understanding of the molecular mechanisms involved in the NDRG2-mediated inhibition of HSCs activation, the mRNA levels of the intracellular mediators of TGF-β1 signal transduction Smad2, Smad3 and Smad7 were analyzed. The results demonstrated that the transcription of all three Smads increased in TGF-β1–treated LX-2 cells; however, AdNDRG2 only attenuated the increase in Smad3 induced by TGF-β1, while Smad2 and Smad7 showed no differences among compared groups (Figure 3A). Furthermore, the protein levels of Smad2/3/7 as well as the phosphorylation of Smad 2/3 were upregulated in the presence of TGF-β1 stimulation, while AdNDRG2 treatment only inhibited the protein level and the phosphorylation status of Smad3 (Figure 3B).

MMPs and TIMPs contribute to both the progression and regression of liver fibrosis. In this study, the expression of both MMP2 and TIMP2 increased during LX-2 activation induced by TGF-β1; however, after AdNDRG2 infection, MMP2 was enhanced while TIMP2 levels decreased (Figure 3C) compared with AdLacZ controls (MMP9 and TIMP1 were undetectable). Consequently, the ratio of MMP2 to TIMP2 was increased (Table 1), which is helpful for the regression of ECM accumulation.

**NDRG2 attenuates DMN-induced liver fibrosis**

To explore the anti-fibrosis role of NDRG2 in vivo, a rat liver fibrosis model was established by DMN injection. Rats receiving DMN treatment developed severe fibrosis as shown in a representative hematoxylin and eosin (H&E) and Sirius Red stained image (Figure 4A). In addition, the expression of NDRG2 in liver cells decreased while α-SMA positive cells increased dramatically (Figure 5A), indicating that HSCs had been activated following DMN treatment.

To determine the infection efficacy of the adenovirus, rats were injected first with phosphate buffered saline (PBS) or a single dose of adenoviral vector (4×10⁹ plaque forming units [PFU]) expressing enhanced green fluorescent protein (AdEGFP) via the tail vein. Forty-eight hours after injection, over 80% of liver cells were EGFP-positive compared with the PBS group (Figure S2A), showing that the adenovirus had a high infection efficiency. In addition, we found that after administration of the same dose of AdNDRG2, NDRG2 levels were significantly enhanced in rat liver from day three to day 14 (Figure S2B) while AdLacZ treatment had no effect on NDRG2 expression (Figure S2C).

Thus, a single dose of adenovirus was enough to enhance NDRG2 expression, which lasted long enough to produce a therapeutic effect on liver fibrosis.

After treatment, we observed that, compared with PBS or AdLacZ injection, AdNDRG2 administration not only elevated NDRG2 expression in liver cells but also inhibited the expression of α-SMA (Figure 5), which demonstrated further that NDRG2
could suppress HSCs activation. In addition, the degree of fibrosis was significantly attenuated as revealed by H&E and Sirius Red staining (Figure 4A and B). Meanwhile, after AdNDRG2 injection, the hydroxyproline content, which is an indicator for ECM deposition, was decreased in the AdNDRG2-treated fibrotic livers (199.69 ± 8.23 µg/mg) compared with the AdLacZ group.

Figure 1. NDRG2 is decreased during LX-2 activation. (A) Green (FITC conjugated) represented NDRG2 expression while red (CY3 conjugated) represented α-SMA expression in LX-2 cells, DAPI (blue)-stained nuclei (400×). Real-time PCR (B) and Western blotting (C) were used to detect the expression of α-SMA and NDRG2 in LX-2 cells grown to confluence and then replated on 100 mm dishes for 12 days. Real-time PCR (D) and Western blotting (E) were used to detect the expression of α-SMA and NDRG2 in LX-2 cells following serum starvation and supplementing with 0.2% BSA for 48 hours prior to PBS or TGF-β1 treatment (2.5 ng/ml for 24 hours). β-actin was used as a loading control. All experiments were performed independently in triplicate. *P<0.05 between compared groups. doi:10.1371/journal.pone.0027710.g001

Figure 2. NDRG2 inhibits HSCs activation. NDRG2 mRNA (A) and protein (B) level in LX-2 cells assessed 48 hours after PBS or adenovirus infection. α-SMA mRNA (C) and protein (D) level in LX-2 cells assessed after PBS, TGF-β1 and/or adenovirus infection. β-actin was used as a loading control. Relative quantifications of α-SMA band intensities, normalized to β-actin levels, were shown below blots. All experiments were performed independently in triplicate. In (A), *P<0.05 compared with the PBS or AdLacZ group. In (C), *P<0.05 compared with the TGF-β1+AdLacZ group; **P<0.05 compared with the AdLacZ or PBS group. doi:10.1371/journal.pone.0027710.g002
In line with the in vitro results, the data obtained from fibrotic rats indicated that, following AdNDRG2 treatment, the expression and phosphorylation of Smad3 decreased while the ratio of MMP2 to TIMP2 increased (Figure 6) (Table 2), confirming that the regulatory role of NDRG2 in TGF-β1/Smad signaling and in the regulation of MMP2 and TIMP2 expression contributes towards its therapeutic effects in the fibrotic liver.

NDRG2 increases hepatocyte proliferation and improves liver function

Our previous data demonstrated that AdNDRG2 treatment induced hepatocyte cell cycle arrest and apoptosis in vitro [28]. However, in the present study, it is important to note that hepatocytes responded differently to AdNDRG2 in DMN-induced liver fibrosis. Proliferating cell nuclear antigen (PCNA) staining and BrdU staining increased in AdNDRG2 group compared with PBS or AdLacZ group while TUNEL analysis revealed that AdNDRG2 had no effect on inducing hepatocyte apoptosis (Figure 7) (Figure S3), which indicating that AdNDRG2 not only inhibited HSCs activation and ECM accumulation, but also facilitated the regression of liver fibrosis by enhancing the proliferation of hepatocytes without inducing apoptosis. Moreover, AdNDRG2 injection significantly improved hepatic serum biochemical parameters in the DMN-induced rat fibrotic model (Table 3).

Discussion

HSCs can undergo further activation either by cultured on uncoated plastic or treated with TGF-β1. These two models are well-established techniques for studying hepatic fibrogenesis at the cellular level. The present data demonstrated a decrease in NDRG2 expression using both of these methods for HSCs activation. Previous studies have revealed that the level of NDRG2 expression is linked positively to cell differentiation and negatively to cell proliferation [16,17,29,30,31], and it is well known that during chronic liver injury, HSCs activation involves the process of transdifferentiating from quiescent into proliferative and ECM-producing myofibroblasts [32]. Thus, the decrease in NDRG2 levels during the HSCs activation process is another evidence for the regulatory role of NDRG2 on cell differentiation and proliferation. Taking this into account, whether or not NDRG2 regulates the proliferative ability and transdifferentiation process of HSCs merits further investigation.

TGF-β1 is a profibrogenic cytokine in the liver. The current study has shown that NDRG2 inhibited HSCs activation in the absence and presence of TGF-β1, and in addition, increased the expression of MMP2 in HSCs. These results differ partly from
research into HCC, which revealed that overexpression of NDRG2 antagonized TGF-β1–mediated HCC invasion by down-regulating MMP2 expression [22]. However, the previous study was based on the HCC cell line PLC/PRF/5. Most cases of HCC develop on a liver fibrosis background [33] and a fibrous capsule surrounds a typical HCC at an early stage [34]. HCC cells have to degrade the ECM and basement membrane during the process of metastasis [35]. Therefore, overexpression of NDRG2 leads to reduced MMP2 and ECM degradation, which subsequently, confined HCC to its fibrous septa. Yet, in our study, AdNDRG2 treatment produced an increase in MMP2 as well as a decrease of TIMP2. MMP2 activity is regulated at the cell surface and involves the formation of a tri-molecular complex consisting of pro-MMP2, MT1-MMP and TIMP-2. All three components of this complex are expressed by activated HSCs [36]. An increase in MMPs and TIMPs is common in fibrotic diseases, while an alteration in the MMP/TIMP expression ratio is known to be critical in determining matrix remodeling [10]. In this study, the data from LX-2 cells demonstrated that over-expressing NDRG2 inhibited the expression of TIMP2 and increased MMP2. Consequently, NDRG2 administration reduced ECM deposition within the liver parenchyma and alleviated liver fibrosis.

Figure 4. NDRG2 attenuates DMN-induced liver fibrosis. PBS or adenovirus was injected four weeks after DMN treatment and rats were sacrificed two weeks after injection. (A) Liver fibrosis was assessed by H&E staining (100×) and Sirius Red staining (40×). (B) Semi-quantitative analysis of the Sirius Red staining result. (C) Assay of hydroxyproline content. The data are expressed as hydroxyproline (μg)/wet liver weight (mg). Three samples were determined from each group. “normal” means rats without treatment. *P<0.05 compared with PBS or AdLacZ group.
doi:10.1371/journal.pone.0027710.g004

A recent study from our laboratory revealed that the overexpression of NDRG2 in a hepatocyte cell line resulted in G1/S arrest and apoptosis induction. During the early phase of liver regeneration in a rat partial hepatectomy (PH) model, NDRG2 was down-regulated, which may have facilitated hepatocyte proliferation [28]. Based on these data, we wondered whether AdNDRG2 treatment could inhibit hepatocyte proliferation and cause apoptosis in fibrotic rat liver, which were harmful for liver fibrosis treatment. However, in our current study, enhanced PCNA and BrdU staining in the fibrotic liver implied that AdNDRG2 injection increased the proliferation of hepatocytes. In addition, TUNEL analysis revealed that there were no significant differences between the numbers of apoptotic cells in
the AdNDRG2 group and the PBS and AdLacZ-treated groups. The discrepancies between these two studies may be attributed to the complexity of the NDRG2 regulation network in different liver tissue remodeling microenvironments (PH-induced liver regeneration compared to DMN-induced liver fibrosis). In addition, both TGF-β1 and ECM deposition have an anti-proliferative and pro-apoptotic effect on hepatocytes [39]. Thus, in the current study, it is possible that AdNDRG2 treatment exerted its therapeutic function by antagonizing TGF-β1 and subsequently increasing hepatocyte proliferation without inducing cell apoptosis, processes essential for treating liver fibrosis and improving liver function.

Collectively, the data reported in this study have demonstrated, for the first time, that NDRG2 is involved in the regulation of liver fibrosis. NDRG2 expression correlated inversely with HSCs activation and, in addition, inhibited TGF-β1–induced HSCs activation by suppressing Smad3 expression and phosphorylation. Furthermore, the in vivo study indicated that adenovirus-mediated NDRG2 treatment could effectively attenuate liver fibrosis and improve liver function. Thus, it is conceivable that modulating NDRG2 expression may provide a novel therapy for intervention in liver fibrosis.

Materials and Methods

Cell lines and cell culture

LX-2 and HSC-T6 cells [24] were kindly provided by Dr Scott Friedman. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) in a humidified atmosphere of 5% CO2 at 37°C.

Immunofluorescence analysis

Cells were seeded in 24-well plates and treated with 4% paraformaldehyde for 15 min at 4°C. After blocking with 1% bovine serum albumin (BSA) in PBS containing 0.1% Triton X-100 for 1 hour at room temperature, the cells were incubated with primary NDRG2 (Abnova, Taiwan, China) or α-SMA (Abcam, Cambridge, MA, USA) antibodies overnight at 4°C, followed by three washes with PBS and incubation for 2 hours with FITC- or CY3-conjugated secondary antibodies (Boster, Wuhan, China). Cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI; Molecular Probes, OR).

TGF-β1 treatment

Cells were plated in 100 mm dishes. Once they reached 70% confluence, the cells were serum starved and supplemented with 0.2% BSA for 48 hours. Next, TGF-β1 (2.5 ng/ml, PeproTech, Rocky Hill, NJ, USA) was added for 24 hours.

Adenovirus infection

Adenoviral vectors expressing human or rat NDRG2 (AdNDRG2), the negative control, β-galactosidase (AdLacZ), and enhanced green fluorescent protein (AdEGFP) were pur-
chased from Benyuan Zhengyang Company (Beijing, China). Cells were seeded in 100 mm dishes and treated with AdNDRG2, AdLacZ or PBS in serum-free DMEM for 2 hours. The medium was replaced with fresh DMEM supplemented with 10% FBS and incubated for 48 hours. The multiplicity of infection (MOI) was 40, which was determined according to preliminary experimental results.

Animals

Seven-week-old male Sprague-Dawley rats weighing between 200 and 225 g were housed individually in cages with a 12 hour light-dark cycle and given free access to water and standard rat chow throughout the study. All experimental procedures were conducted in accordance with the ‘Detailed Rules for the Administration of Animal Experiments for Medical Research Purposes’ issued by the Ministry of Health of China and had received ethical approval (Permit number: SCXK 2007-007) by the Animal Experiment Administration Committee of the Fourth Military Medical University (Xi’an, P.R., China). All efforts were made to minimize animals’ suffering and to reduce the number of animals used.

Fibrosis model and tissue preparation

Rats were injected intraperitoneally with 1% DMN (10 mg/kg) for three consecutive days per week for up to five weeks. After 12 DMN injections, rats were infused with PBS or a single dose of 4 x 10^9 PFU of AdLacZ or AdNDRG2 via the tail vein (ten rats in each group). Two weeks after gene delivery, animals were sacrificed and liver samples were collected. For 5'-Bromo-2'-deoxyuridine (BrdU) staining, one hour before sacrifice, 100 mg BrdU (Sigma, St. Louis, MO) per kg body weight was injected intraperitoneally. RNA and protein were extracted directly with standard techniques described below as soon as the liver samples were excised. For immunohistochemistry analysis, samples were fixed with neutral buffered 4% paraformaldehyde overnight at 4°C, and liver sections of 10 μm thickness were prepared using a cryostat microtome (Leica, Solms, Germany) and fixed to poly-L-lysine–coated glass slides. Sections were stored at -20°C until required.

Immunohistochemistry analysis

Sections were deparaffinized in xylene and dehydrated through a graduated alcohol series. After incubating with 0.3% H2O2 in

![Figure 6. NDRG2 affects the TGF-β1/Smad signaling pathway and the ratio of MMP2 to TIMP2 in rats.](image)

(A) Real-time PCR was used to detect the expression of Smad2, Smad3 and Smad7 in rats with PBS or adenovirus treatment. (B) Western blotting was used to detect the expression of Smad2, phospho-Smad2, Smad3, phospho-Smad3 and Smad7 in rats with PBS or adenovirus treatment. (C) Real-time PCR was used to detect the expression of MMP2 and TIMP2 in rats following PBS or adenovirus treatment. β-actin was used as a loading control. “normal” means rats without treatment. *P<0.05 compared with the PBS or AdLacZ group.

doi:10.1371/journal.pone.0027710.g006

| Table 2. NDRG2 affects the ratio of MMP2 to TIMP2 in rats. |
|-----------------|-----------------|
| Group          | MMP2/TIMP2      |
| normal         | 1               |
| PBS            | 0.749±0.0076    |
| AdNDRG2        | 2.640±0.2891*   |
| AdLacZ         | 0.615±0.0125    |

*P<0.05 compared with the PBS or AdLacZ group. “normal” means rats without treatment.
doi:10.1371/journal.pone.0027710.t002
methyl alcohol for 15 min, sections were treated with citrate buffer (pH 6.0) for antigen retrieval and incubated with 10% normal goat serum in PBS for 1 hour at room temperature to block nonspecific binding. Then, the sections were incubated with the following primary antibodies in PBS at 4°C overnight: mouse anti-NDRG2 (1:100; Abnova), mouse anti-PCNA (1:2000; Cell Signaling Technology, Danvers, MA, USA), rabbit anti-α-SMA (1:100; Abcam), and mouse anti-BrdU (1:100; Santa Cruz Biotechnology, CA, USA). After equilibrating to room temperature, sections were first incubated with biotinylated goat anti-mouse/rabbit IgG (1:400, Sizhengbo, Beijing, China) for 2 hours and then treated with a streptavidin-horseradish peroxidase complex (Sizhengbo) for 1 h at room temperature. Staining was examined by incubation with 3,3′-diaminobenzidine (DAB) and the sections were counterstained with hematoxylin and viewed under a light microscope.

Sirius Red staining

Sections were deparaffinized and the slides were incubated for 10 min in celestine blue solution and washed with distilled water three times. Next, the slides were placed in a solution of saturated picric acid containing 0.05% Sirius Red for 30 min. After washing with 100% ethanol, slides were mounted in mounting media and covered with a coverslip. The results of Sirius Red staining were quantified with Image-Pro Plus software 6.0 (Media Cybernetics, L.P., Silver Spring, MD).

Apoptotic cell staining

For apoptosis detection in frozen liver tissue sections, terminal deoxynucleotidyl transferase-mediated deoxynucleotide triphosphate nick-end labeling (TUNEL) staining was performed as described in the manufacturer’s instructions (Roche, Indianapolis, IN, USA). Staining was visualized by fluorescence microscopy (Olympus, Center Valley, PA).

Hepatic function and hydroxyproline content

An automated analyzer at the Department of Pharmacology in the Fourth Military Medical University was used to analyze serum parameters.

### Table 3. NDRG2 improves hepatic serum biochemical parameters.

| Group    | ALB (g/l) | ALT (U/l) | AST (U/l) |
|----------|-----------|-----------|-----------|
| normal   | 36.5±3.2  | 43.1±7.2  | 92.4±14.9 |
| PBS      | 15.4±1.6  | 208.2±9.8 | 251.4±32.7|
| AdNDRG2  | 26.6±4.8* | 156.6±25.7| 173.8±10.0 |
| AdLacZ   | 13.1±0.7  | 218.7±12.4| 279.2±35.5|

*P<0.05 compared with the PBS or AdLacZ group. “normal” means rats without treatment.
biochemical parameters, and 100 mg of wet liver samples were subjected to acid hydrolysis to measure the hydroxyproline content according to the Hydroxyproline Testing Kit (Jiancheng, Nanjing, China) protocol.

Real-time PCR
Total RNA was isolated from each sample using TRIzol reagent (Invitrogen) and then quantified. The cDNA was synthesized from 5 μg of each RNA sample with a Taqman reverse transcriptase reagent kit (Applied Biosystems, UK) primed with oligo(dT) and then was used as a template for real-time quantitative PCR analysis. The sequences of the primers are listed in Table 4. The mRNAs were detected with SYBR Green PCR Master Mix and an ABI PRISM 7500 Sequence Detection System (Applied Biosystems) using the comparative threshold cycle method for relative quantification. The PCR reaction consisted of 12.5 μl of template cDNA in a total volume of 25 μl. The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 s, followed by 45 cycles at 95°C for 5 s and 60°C for 34 s.

Western blot analysis
Cells were harvested from 100 mm culture dishes. Both cells and liver tissues were lysed in 200 μl RIPA buffer (0.05 M Tris-HCl [pH 7.4], 0.15 M NaCl, 0.25% deoxycholic acid, 1% Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin and 10 μg/ml leupeptin). Protein concentrations were measured using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). Proteins were resolved by SDS-PAGE and transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). The blots were probed with the following primary antibodies: NDRG2 (Abnova), β-actin, Smad7 (Santa Cruz Biotechnology), α-SMA (Abcam), Smad2/phospho-Smad2 (pSmad2), Smad3/phospho-Smad3 (pSmad3) (Cell Signaling Technology), followed by incubation with species-matched secondary antibodies. The bands were detected using enhanced chemiluminescence (Pierce) or the Odyssey Imaging System (Li-Cor Biosciences). Band intensities were quantified with Kodak Digital Science 1D 3.0 (Eastman Kodak, New Haven, CT).

Table 4. Primers for Real-time PCR.

| Genes   | Forward primer (5’-3’)         | Reverse primer (5’-3’)         |
|---------|--------------------------------|--------------------------------|
| Human NDRG2 | GAGATATGTCCTTAAACACCCCG      | GCTGCCCAATCCATCAGA             |
| α-SMA   | GACATTGGCTTCGAGTCCTGTA       | CTGTGCTCTGACCCACCTGTA         |
| Smad2   | TTAACCCAAATGCGGAGGTAAGA      | GCTCCAGCAAAAGTTGCACTACGTA     |
| Smad3   | ACGGCTGAGTCCAGACTCACC       | CAGCAACTCTGGTTGTTGGA          |
| Smad7   | TGCGTGTGGAAGTTGGAGTAGT       | CCATCGGTATCTGGAGTTAGG         |
| MMP2    | ATGACATCAAGGGCATCCAGGAG      | TCTGACGCGATCCATAACTACA        |
| TIMP2   | GACCGCCAAGTGACATCACTAC       | GAGATGTAACGCGGACCACATGG       |
| β-actin | AGCGGAGCAATCCCCAAAGATT      | GGCGACGAAAGGCTATCATT          |
| Rat NDRG2 | ATGGCAGAGCTTTCAGAGG         | CCGGTGGTTCAGAGGTAT            |
| α-SMA   | CCGAGATGCAACCGACTACC       | TCCAGAGCGACATCACAG            |
| Smad2   | TATAGATCCATGAATCCGGGA        | CATCTAGGCCTCGGGACACAC         |
| Smad3   | CCAATGAACACGACATGGA         | CTACGTGTCAATGGAGCTGTTGA       |
| Smad7   | CTTTAGCCAGATTGACGACGAG      | CTGTTGTCCGAATGGACTGCTG        |
| MMP2    | TCCCGAGATCTGCGACCAAGAG     | AGAATGCGGCCACGACGAG           |
| TIMP2   | GACGCGATCTTACATCCAGGAG     | CTGTGACAGTCGCACTGCAGAG        |
| β-actin | AGCGTGAAGAAAGATGACCCAGAT    | AACCCTCATGAT1GGGCCAGT         |

doi:10.1371/journal.pone.0027710.t004

Western blot analysis
Cells were harvested from 100 mm culture dishes. Both cells and liver tissues were lysed in 200 μl RIPA buffer (0.05 M Tris-HCl [pH 7.4], 0.15 M NaCl, 0.25% deoxycholic acid, 1% Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin and 10 μg/ml leupeptin). Protein concentrations were measured using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). Proteins were resolved by SDS-PAGE and transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). The blots were probed with the following primary antibodies: NDRG2 (Abnova), β-actin, Smad7 (Santa Cruz Biotechnology), α-SMA (Abcam), Smad2/phospho-Smad2 (pSmad2), Smad3/phospho-Smad3 (pSmad3) (Cell Signaling Technology), followed by incubation with species-matched secondary antibodies. The bands were detected using enhanced chemiluminescence (Pierce) or the Odyssey Imaging System (Li-Cor Biosciences). Band intensities were quantified with Kodak Digital Science 1D 3.0 (Eastman Kodak, New Haven, CT).

Statistical analysis
Statistical analyses were performed with SPSS software (version 16.0; SPSS, Chicago, IL, USA) using the t-test and analysis of variance of independent groups. Statistical significance was based on a value of P<0.05.

Supporting Information
Figure S1 NDRG2 is decreased during HSC-T6 activation. (A) NDRG2 was expressed in LX-2 and HSC-T6 cells. Western blotting (B) and real-time PCR (C) were used to detect the expression of α-SMA and NDRG2 in HSC-T6 cells grown to confluence and then replated on 100 mm dishes for 12 days. β-actin was used as a loading control. All experiments were performed independently in triplicate. *P<0.05 between compared groups.

Figure S2 Adenovirus has a high infection efficiency and significantly enhanced NDRG2 expression in rat liver. (A) Rats were injected with PBS or a single dose (4×10⁹ PFU) of AdEGFP via the tail vein. Then, 48 hours after injection, rats were sacrificed and liver samples were fixed with neutral buffered 4% paraformaldehyde overnight at 4°C in the dark. Liver sections (10 μm thick) were prepared on a cryostat microtome and fixed to glass slides. Sections were examined directly under a fluorescent microscope (100×). (B) Rats were treated with a single dose (4×10⁹ PFU) of AdNDRG2 or AdLacZ via the tail vein. Over the next 14 days, rats were sacrificed at the time points indicated. Liver samples were collected and proteins were extracted directly. NDRG2 expression was examined by Western blotting. β-actin was used as a loading control.
Figure S3  NDRG2 promotes hepatocyte proliferation. (A) Immunohistochemistry staining was used to determine the expression of BrdU (200×) in DMN-induced fibrotic rat livers following PBS or adenosine treatment. (B) Semiquantitative analysis of BrdU staining. *P<0.05 compared with the PBS or AdLacZ group.

Acknowledgments
We especially thank Dr Scott Friedman for providing HSC-T6 and LX-2 cell lines. We thank Prof. Huijie Bian for insightful suggestions and technical help with the cell culture and treatment.

Author Contributions
Conceived and designed the experiments: JY LY KD. Performed the experiments: JY JZ YL MS LX NX. Analyzed the data: JY HZ XW. Contributed reagents/materials/analysis tools: DW XL LY KD. Wrote the paper: JY JZ YL MS.

References
1. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674–687.
2. Bruix J, Boix I, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer Cell 2: 115–219.
3. Hadziyannis SJ, Tassopoulos NC, Heathcote EI, Chang TT, Kitis G, et al. (2006) Long-term therapy with adefovir dipivoxil for HBsAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743–1751.
4. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, et al. (2007) Sustained virologic response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45: 579–587.
5. Veldh J, Heathcote EI, Wedemeyer H, Reichen J, Hofmann WP, et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: 677–684.
6. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209–218.
7. Friedman SL (2004) Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1: 96–105.
8. Dooly S, Steverkert M, Delvoux B, Gressner AM (2001) Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun 283: 554–562.
9. Inagaki Y, Okazaki I (2007) Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284–292.
10. Iredale JP (2001) Hepatocellular cell behavior during resolution of liver injury. Semin Liver Dis 21: 427–436.
11. Okamoto K, Mimura K, Murawaki Y, Yuraku I (2005) Association of gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-9 and MMP-12 with the progression of chronic liver disease. J Gastroenterol Hepatol 20: 1102–1108.
12. Senties-Gomez MD, Galvez-Gastelum FJ, Meza-Garcia E, Armendariz-Borunda J (2005) Hepatic fibrosis: role of matrix metalloproteases and tissue inhibitors. J Cell Physiol 205: 215–221.
13. Zhang J, Liu J, Li X, Li F, Wang L, et al. (2007) The physical and functional interaction of NDRG2 with MSIP58 in cells. Biochem Biophys Res Commun 352: 6–11.
14. Scicluna P, Kim KD, Kim JT, Kim JW, Yoon DY, et al. (2003) Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett 533: 413–418.
15. Nichols NR, Agellon L, Zieba M, Bye N (2005) Glucocorticoid regulation of gial responses during hippocampal neurodegeneration and regeneration. Brain Res Brain Res Rev 48: 257–301.
16. Tanimura M, Swenson ES, Gaca MD, Reiss M, et al. (2005) Smad2 and Smad3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 278: 35162–35169.
17. Otten J, Van der Plas AV, Kool M, Van der Velden VA, et al. (2000) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34: 82–91.
18. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, et al. (2000) Involvement of Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. In Vivo 15: 71–76.
19. Nichols NR, Agellon L, Zieba M, Bye N (2005) Glucocorticoid regulation of gial responses during hippocampal neurodegeneration and regeneration. Brain Res Brain Res Rev 48: 257–301.
20. Shon SK, Kim A, Kim JY, Kim KL, Yang Y, et al. (2009) Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun 385: 198–203.